Savara Inc (NASDAQ:SVRA) Director David A. Ramsay purchased 58,357 shares of the business’s stock in a transaction on Friday, June 28th. The shares were acquired at an average cost of $2.37 per share, with a total value of $138,306.09. Following the acquisition, the director now directly owns 64,685 shares in the company, valued at $153,303.45. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Savara stock traded down $0.01 during midday trading on Friday, reaching $2.49. The company’s stock had a trading volume of 257,184 shares, compared to its average volume of 563,736. Savara Inc has a 52 week low of $2.32 and a 52 week high of $13.25. The company has a current ratio of 12.05, a quick ratio of 12.05 and a debt-to-equity ratio of 0.24. The firm’s 50-day moving average is $4.66. The firm has a market cap of $89.22 million, a PE ratio of -1.93 and a beta of 0.23.
Savara (NASDAQ:SVRA) last released its earnings results on Thursday, May 9th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.05. Research analysts anticipate that Savara Inc will post -1.62 EPS for the current fiscal year.
Several hedge funds have recently made changes to their positions in the company. Metropolitan Life Insurance Co NY acquired a new stake in shares of Savara during the first quarter valued at about $83,000. MetLife Investment Advisors LLC acquired a new position in shares of Savara in the first quarter worth approximately $116,000. DekaBank Deutsche Girozentrale lifted its stake in shares of Savara by 19.4% in the first quarter. DekaBank Deutsche Girozentrale now owns 12,300 shares of the company’s stock worth $141,000 after acquiring an additional 2,000 shares during the period. Alps Advisors Inc. lifted its stake in shares of Savara by 4.5% in the first quarter. Alps Advisors Inc. now owns 84,850 shares of the company’s stock worth $625,000 after acquiring an additional 3,670 shares during the period. Finally, Mesirow Financial Investment Management Inc. lifted its stake in shares of Savara by 46.9% in the first quarter. Mesirow Financial Investment Management Inc. now owns 41,332 shares of the company’s stock worth $305,000 after acquiring an additional 13,187 shares during the period. 45.71% of the stock is currently owned by hedge funds and other institutional investors.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Featured Article: Momentum Investing
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.